Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Aprea Therapeutics (Nasdaq: APRE) announced that four abstracts have been accepted for poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from October 23-25, 2024. The posters showcase progress in Aprea's oncology pipeline of DNA damage response (DDR) inhibitors, featuring updates on two clinical-stage candidates: APR-1051 and ATRN-119.
The presentations include two clinical posters on the safety and efficacy of APR-1051 (a WEE1 inhibitor) and ATRN-119 (a novel macrocyclic ATR inhibitor) in patients with advanced cancers. Additionally, two preclinical posters will be presented, focusing on APR-1051's favorable characteristics for treating CCNE1-overexpressing cancers and the development of macrocyclic ATR inhibitors for cancer treatment.
Aprea Therapeutics (Nasdaq: APRE) ha annunciato che quattro abstract sono stati accettati per la presentazione in formato poster al Simposio EORTC-NCI-AACR sui Target Molecolari e le Terapie per il Cancro a Barcellona, in Spagna, dal 23 al 25 ottobre 2024. I poster mostrano i progressi della pipeline oncologica di Aprea di inibitori della risposta al danno del DNA (DDR), con aggiornamenti su due candidati in fase clinica: APR-1051 e ATRN-119.
Le presentazioni includono due poster clinici sulla sicurezza e l'efficacia di APR-1051 (un inibitore WEE1) e ATRN-119 (un nuovo inibitore macrocyclic ATR) in pazienti con cancro avanzato. Inoltre, saranno presentati due poster preclinici, focalizzati sulle caratteristiche favorevoli di APR-1051 nel trattamento dei tumori con sovraespressione di CCNE1 e sullo sviluppo di inibitori macrocyclic ATR per la terapia oncologica.
Aprea Therapeutics (Nasdaq: APRE) anunció que se han aceptado cuatro resúmenes para presentación en formato poster en el Simposio EORTC-NCI-AACR sobre Objetivos Moleculares y Terapias para el Cáncer en Barcelona, España, del 23 al 25 de octubre de 2024. Los posters muestran el progreso en la plataforma oncóloga de Aprea de inhibidores de la respuesta al daño del ADN (DDR), con actualizaciones sobre dos candidatos en fase clínica: APR-1051 y ATRN-119.
Las presentaciones incluyen dos posters clínicos sobre la seguridad y eficacia de APR-1051 (un inhibidor de WEE1) y ATRN-119 (un nuevo inhibidor macrocíclico de ATR) en pacientes con cánceres avanzados. Además, se presentarán dos posters preclínicos centrados en las características favorables de APR-1051 para tratar cánceres con sobreexpresión de CCNE1 y el desarrollo de inhibidores macrocíclicos de ATR para el tratamiento del cáncer.
Aprea Therapeutics (Nasdaq: APRE)는 2024년 10월 23일부터 25일까지 스페인 바르셀로나에서 열리는 EORTC-NCI-AACR 분자 타겟 및 암 치료 심포지엄에 포스터 발표를 위해 네 개의 초록이 수락되었다고 발표했습니다. 이 포스터들은 DNA 손상 반응(DDR) 억제제에 대한 Aprea의 항암제 파이프라인의 진전을 보여주며, 두 개의 임상단계 후보인 APR-1051과 ATRN-119에 대한 업데이트를 포함하고 있습니다.
발표에는 진단이 복잡한 암 환자를 위한 APR-1051 (WEE1 억제제) 및 ATRN-119 (신종 macrocyclic ATR 억제제)의 안전성과 효능에 대한 두 개의 임상 포스터가 포함되어 있습니다. 또한 CCNE1이 과발현된 암 치료에 있어 APR-1051의 유리한 특성과 암 치료를 위한 macrocyclic ATR 억제제 개발에 중점을 둔 두 개의 전임상 포스터도 발표될 예정입니다.
Aprea Therapeutics (Nasdaq: APRE) a annoncé que quatre résumés avaient été acceptés pour une présentation par affiche au Symposium EORTC-NCI-AACR sur les cibles moléculaires et les thérapies anticancéreuses à Barcelone, en Espagne, du 23 au 25 octobre 2024. Les affiches mettent en valeur les progrès de la pipeline oncologique d'Aprea avec des inhibiteurs de la réponse aux dommages de l'ADN (DDR), comprenant des mises à jour sur deux candidats en phase clinique : APR-1051 et ATRN-119.
Les présentations comprennent deux affiches cliniques sur la sécurité et l'efficacité d'APR-1051 (un inhibiteur de WEE1) et d'ATRN-119 (un nouvel inhibiteur macrocyclique de l'ATR) chez des patients atteints de cancers avancés. De plus, deux affiches précliniques seront présentées, axées sur les caractéristiques favorables d'APR-1051 pour traiter les cancers avec surexpression de CCNE1 et le développement d'inhibiteurs macrocycliques de l'ATR pour le traitement du cancer.
Aprea Therapeutics (Nasdaq: APRE) gab bekannt, dass vier Abstracts für die Posterpräsentation beim EORTC-NCI-AACR-Symposium zu molekularen Zielen und Krebstherapien in Barcelona, Spanien, vom 23. bis 25. Oktober 2024, akzeptiert wurden. Die Poster zeigen Fortschritte in der Onkologie-Pipeline von Aprea mit DNA-Schadenreaktion (DDR) Inhibitoren, einschließlich Aktualisierungen zu zwei Kandidaten in der klinischen Phase: APR-1051 und ATRN-119.
Die Präsentationen umfassen zwei klinische Poster zur Sicherheit und Wirksamkeit von APR-1051 (einem WEE1-Inhibitor) und ATRN-119 (einem neuartigen makrozyklischen ATR-Inhibitor) bei Patienten mit fortgeschrittenen Krebserkrankungen. Zusätzlich werden zwei präklinische Poster vorgestellt, die sich auf die vorteilhaften Eigenschaften von APR-1051 zur Behandlung von CCNE1-überexprimierenden Krebserkrankungen und die Entwicklung von makrozyklischen ATR-Inhibitoren zur Krebsbehandlung konzentrieren.
- Four abstracts accepted for poster presentation at a major oncology symposium
- Showcasing progress in the company's oncology pipeline of DNA damage response inhibitors
- Presenting updates on two clinical-stage candidates: APR-1051 and ATRN-119
- None.
DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that four abstracts have been accepted for poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, October 23 - 25, 2024. Details on the posters are below.
"We are very pleased to have these posters featured at the upcoming EORTC-NCI-AACR Symposium, showcasing the ongoing progress in our oncology pipeline of DNA damage response (DDR) inhibitors," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "This symposium provides a great opportunity to share updates on our two clinical stage candidates, APR-1051 and ATRN-119, with the international oncology community.”
Poster Details
| Clinical: | ||
| Title: | Safety and Preliminary Efficacy of APR-1051, a WEE1 Inhibitor, in a Phase 1 Study of Patients with Cancer-Associated Gene Alterations (ACESOT-1051) | |
| Session date/ time: | Wednesday, October 23rd, 12:00 - 19:00 CET | |
| Location: | Exhibition Hall | |
| Poster #: | 77 | |
| Title: | ATRN-119, a Novel Macrocyclic ATR Inhibitor, in Patients with Advanced Solid Malignancies: A Phase 1/2a Trial (ABOYA-119) | |
| Session date/ time: | Friday, October 25th, 09:00 - 15:00 CET | |
| Location: | Exhibition Hall | |
| Poster#: | 348 | |
| Preclinical | ||
| Title: | The novel WEE1i, APR-1051, does not substantially off-target PLK1, PLK2, or PLK3 and exhibits favorable in vivo characteristics for treating CCNE1-overexpressing cancers | |
| Session date/ time: | Friday, October 25th, 09:00 - 15:00 CET | |
| Location: | Exhibition Hall | |
| Poster #: | 335 | |
| Title: | Development and testing of a first-in-class series of macrocyclic ATR inhibitors for cancer treatment | |
| Session date/ time: | Friday, October 25th, 09:00 - 15:00 CET | |
| Location: | Exhibition Hall | |
| Poster #: | 336 | |
Copies of the posters will be available on the “Investor Resources” page of the Aprea corporate website at the conclusion of the meeting.
Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website https://aprea.com/.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
FAQ
What is the date and location of the EORTC-NCI-AACR Symposium where Aprea Therapeutics (APRE) will present?
How many abstracts from Aprea Therapeutics (APRE) were accepted for presentation at the symposium?
What are the two clinical-stage candidates that Aprea Therapeutics (APRE) will present updates on?
What is the focus of Aprea Therapeutics' (APRE) oncology pipeline?
